Publications by authors named "Ruby S Gibson"
Cumulative life course impairment: Evidence for hidradenitis suppurativa.
J Eur Acad Dermatol Venereol
August 2025
Hidradenitis suppurativa (HS) adversely affects quality of life, education, work, relationships and mental health. The debilitating effects of HS can compound over a patient's lifetime and have lasting repercussions. The cumulative life course impairment (CLCI) model analyses the disease factors that could affect the life course trajectory of a patient, including effects on major life decisions and opportunities, such as relationships, career path, education and starting a family.
View Article and Find Full Text PDFBackground: In some hidradenitis suppurativa (HS) clinical trial study arms, there is an unexpected decline in efficacy between the penultimate visit and the prespecified primary endpoint week, which we have termed a "wobble."
Objective: We aimed to establish how often study arms in HS programs wobble.
Methods: In a retrospective review, we identified HS clinical trials listed on ClinicalTrials.
Evaluating minority representation across health care settings in hidradenitis suppurativa and psoriasis.
Int J Womens Dermatol
March 2024
Background: Females and minorities have been underrepresented in clinical research despite legislative efforts, including in hidradenitis suppurativa (HS) and psoriasis (PsO) clinical trials.
Objective: To identify differences in demographic breakdowns of HS and PsO patients between health care settings to uncover any causative health disparities.
Methods: This study reports racial, ethnic, and sex of HS and PsO patient populations across the emergency department (ED), inpatient, clinical trial, and registry settings.
Article Synopsis
- - The IL-17 pathways play a key role in inflammatory skin conditions, especially hidradenitis suppurativa, which currently has adalimumab as the only FDA-approved treatment.
- - Secukinumab, an IL-17A inhibitor, has been effective for conditions like psoriasis and shows promising results for hidradenitis suppurativa in recent phase III clinical trials.
- - This article explores how secukinumab works and reviews its clinical efficacy and safety for managing hidradenitis suppurativa.
Advances in biologic and small molecule therapies for hidradenitis suppurativa.
Expert Opin Pharmacother
June 2022
Article Synopsis
- * The text reviews clinical trials and studies on various biologic treatments (like TNFα and IL inhibitors) and small molecule inhibitors (like JAK and PDE4 inhibitors) for HS, covering their mechanisms and effects on the body.
- * Some patients see improvement with existing treatments like adalimumab, but there remains a significant need for more effective options, leading to optimism about new therapies under investigation.
Clinical and radiological characteristics of patients with retroperitoneal infantile hemangiomas.
Pediatr Dermatol
November 2019
Background: Infantile hemangiomas (IHs) are the most common tumors of infancy. The objective was to identify clinical and radiological patterns in patients with retroperitoneal IHs.
Methods: We reviewed patients from our Vascular Anomalies Center database with IHs and abdominal imaging presenting from 1999 to 2017 to identify retroperitoneal involvement.
Coccygeal Polypoid Eccrine Nevus Presenting as a Skin Tag: Case Report and Review of the Literature.
Clin Med Insights Case Rep
June 2019
Coccygeal polypoid eccrine nevi (CPEN) are rare, benign, cutaneous polypoid lesions localized to the coccyx region that are characterized by areas of hyperplastic eccrine ducts without hyperhidrosis. We present the case of an asymptomatic 16-month-old female with a congenital lesion in the lower sacral area and review the literature and the differential diagnosis for CPEN.
View Article and Find Full Text PDF